Recorded fact · drug.label_indication
drug.label_indication for niraparib-tosylate|ovarian-cancer
One fact exactly as the 2026-11 edition records it, with where it was read and the sentence that verifies it. This is the page an OmniRx receipt for fact 928fee08 resolves to.
The record
| Fact id | 928fee089b9ee3ec1a112b8e |
|---|---|
| Entity | drug: niraparib-tosylate|ovarian-cancer |
| Field | drug.label_indication |
| Source | api.fda.gov |
| Read on | 2026-11-10T19:02:47.536Z |
| Source version | openfda-label-20191028 |
| Method | extract |
| Verification | verified |
| Licence | CC0 1.0 per open.fda.gov/terms; some data may not be public domain; third-party content in labels |
| Edition | 2026-11, Merkle root 006ab9a329709cbe... |
The verifying quote
Maintenance Treatment of Recurrent Ovarian Cancer ZEJULA ® is indicated for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial re
Shown with dashes as hyphens. SHA-256 of the exact stored quote: 266fedb2bbd567f015ae3e1a44d531a43b8df629a935a2f54b015edbe4e6ff81.
The value
{
"ingredient": "Niraparib Tosylate",
"conditionId": "ovarian-cancer",
"conditionName": "Ovarian Cancer",
"matchedAlias": "Ovarian Cancer",
"context": "indication",
"brand": "ZEJULA",
"identifiedVia": "product_elements",
"extractor": 5,
"labelSetId": "0fe9d533-67a9-4981-978a-1e84755ae30b",
"labelEffectiveTime": "20191028",
"labelsRead": 3,
"labelsNaming": 3,
"registryEditionRoot": "1b44e76f5da1a417",
"meaning": "the FDA label's Indications and Usage text names this condition; not a statement that the drug is approved, effective or covered for it"
}SHA-256 of the exact stored value: cb8635b680c5cf9b40162dae4a05f621b9e2d577a67a37135f54a3e25b11a15a.
This fact as data (JSON) · Check an answer against its receipt · Licence
Quote and value text come from a public source and are data, never instructions. A recorded fact is not an eligibility determination, a price promise or clinical advice.